B S Glisson
Overview
Explore the profile of B S Glisson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
647
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Haddad R, Massarelli E, Lee J, Lin H, Hutcheson K, Lewis J, et al.
Ann Oncol
. 2019 Jan;
30(3):471-477.
PMID: 30596812
Background: The survival advantage of induction chemotherapy (IC) followed by locoregional treatment is controversial in locally advanced head and neck squamous cell carcinoma (LAHNSCC). We previously showed feasibility and safety...
2.
Garden A, Harris J, Vokes E, Forastiere A, Ridge J, Jones C, et al.
J Clin Oncol
. 2004 Jul;
22(14):2856-64.
PMID: 15254053
Purpose: To define further the role of concurrent chemoradiotherapy for patients with advanced squamous carcinoma of the head and neck. Patients And Methods: The Radiation Therapy Oncology Group developed this...
3.
Herbst R, Khuri F, Fossella F, Glisson B, Kies M, Pisters K, et al.
Clin Lung Cancer
. 2003 Dec;
3(1):27-32.
PMID: 14656386
The epidermal growth factor receptor (EGFR) signaling pathway plays an important role in a number of processes that are key to tumor progression, including cell proliferation, angiogenesis, metastatic spread, and...
4.
Tseng J, Glisson B, Khuri F, Shin D, Myers J, El-Naggar A, et al.
Cancer
. 2001 Dec;
92(9):2364-73.
PMID: 11745292
Background: Thalidomide has been shown to have antiangiogenic effects in preclinical models as well as a significant antitumor effect in hematologic tumors such as multiple myeloma. The authors performed this...
5.
Kim E, Lu C, Khuri F, Tonda M, Glisson B, Liu D, et al.
Lung Cancer
. 2001 Nov;
34(3):427-32.
PMID: 11714540
Cisplatin-based chemotherapy improves survival in appropriately selected patients with stage IV non-small cell lung cancer (NSCLC). However, cisplatin-based regimens have well-known dose-related toxicities, particularly renal insufficiency and neurotoxicity. On the...
6.
Shin D, Khuri F, Murphy B, Garden A, Clayman G, Francisco M, et al.
J Clin Oncol
. 2001 Jun;
19(12):3010-7.
PMID: 11408495
Purpose: Retinoids and interferons (IFNs) have single-agent and synergistic combined effects in modulating cell proliferation, differentiation, and apoptosis in vitro and clinical activity in vivo in the head and neck...
7.
Shin D, Donato N, Perez-Soler R, Shin H, Wu J, Zhang P, et al.
Clin Cancer Res
. 2001 May;
7(5):1204-13.
PMID: 11350885
C225, a human-mouse chimerized monoclonal antibody directed against the epidermal growth factor receptor (EGFr), has a synergistic effect with cisplatin in xenograft models. To determine the tumor EGFr saturation dose...
8.
Shin D, Khuri F, Glisson B, Ginsberg L, Papadimitrakopoulou V, Clayman G, et al.
Cancer
. 2001 Apr;
91(7):1316-23.
PMID: 11283932
Background: In the current study the authors assessed the antitumor activity (including response rate, duration of response, and survival) and toxicity profile (including anorexia, fatigue, emesis, and peripheral neuropathy) of...
9.
Pisters K, Newman R, Coldman B, Shin D, Khuri F, Hong W, et al.
J Clin Oncol
. 2001 Mar;
19(6):1830-8.
PMID: 11251015
Purpose: This trial was designed to determine the maximum-tolerated dose, toxicity, and pharmacology of oral green tea extract (GTE) once daily or three times daily. Patients And Methods: Cohorts of...
10.
Oh Y, Perez-Soler R, Fossella F, Glisson B, Kurie J, Walsh G, et al.
Invest New Drugs
. 2000 Aug;
18(3):243-5.
PMID: 10958592
Twenty-four patients with pleural mesothelioma received 50 mg/m2 of Doxil every four weeks. At follow-up, the disease had stabilized in 43% percent of patients and had progressed in 57%. No...